Iovance Biotherapeutics (IOVA) Enterprise Value (2010 - 2026)
Iovance Biotherapeutics (IOVA) posted quarterly Enterprise Value of -$313.4 million for Q1 2026, up 12.86% year-over-year from -$277.7 million in Q1 2025, and down 5.54% quarter-over-quarter from -$297.0 million in Q4 2025.
Iovance Biotherapeutics (IOVA) Enterprise Value (2010 - 2026) Analysis & Trends
Iovance Biotherapeutics (IOVA) has reported Enterprise Value for 16 consecutive years, with -$313.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Enterprise Value rose 12.86% year-over-year to -$313.4 million; the TTM figure through Mar 2026 stood at -$313.4 million (up 12.86% YoY), while the FY2025 annual figure was -$297.0 million, up 8.28% from the prior year.
- Enterprise Value declined to -$313.4 million in Q1 2026 per IOVA's latest filing, from -$297.0 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$164.2 million in Q3 2024 and bottomed at -$626.3 million in Q1 2023.
- Historically, Enterprise Value has averaged -$347.2 million across 5 years, with a median of -$323.8 million in 2024.
- Annual changes were most pronounced in 2024 — Enterprise Value jumped 54.56% — and 2025, when it plunged 83.21%.
- Iovance Biotherapeutics' Enterprise Value stood at -$471.8 million in 2022, then jumped by 40.69% to -$279.9 million in 2023, then declined by 15.69% to -$323.8 million in 2024, then climbed by 8.28% to -$297.0 million in 2025, then declined by 5.54% to -$313.4 million in 2026.
- Business Quant data shows IOVA's Enterprise Value at -$313.4 million in Q1 2026, -$297.0 million in Q4 2025, and -$300.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Iovance Biotherapeutics | 3.16 Bn | 2.86 Bn | 55.72 Mn | -297.71 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -297.71 Mn |
| Mar 31, 2026 | -313.44 Mn |
| Dec 31, 2025 | -296.98 Mn |
| Sep 30, 2025 | -300.80 Mn |
| Jun 30, 2025 | -301.20 Mn |
| Mar 31, 2025 | -359.71 Mn |
| Dec 31, 2024 | -323.78 Mn |
| Sep 30, 2024 | -164.19 Mn |
| Jun 30, 2024 | -228.68 Mn |
| Mar 31, 2024 | -356.20 Mn |
| Dec 31, 2023 | -279.87 Mn |
| Sep 30, 2023 | -361.35 Mn |
| Jun 30, 2023 | -250.90 Mn |
| Mar 31, 2023 | -626.29 Mn |
| Dec 31, 2022 | -471.85 Mn |
| Sep 30, 2022 | -360.17 Mn |
| Jun 30, 2022 | -424.48 Mn |
| Mar 31, 2022 | -482.16 Mn |
| Dec 31, 2021 | -504.41 Mn |
| Sep 30, 2021 | -576.49 Mn |